Find Clinical Trial

An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.


← Back
Study Phase

Phase 3

Therapeutic Area

Cancers

Active substance/
Medical device

TRIFLURIDINE, TIPIRACIL

SponsorLaboratorios Servier S.L.
Active Substance CodeS095005
Protocol CodeCL3-95005-004
EudraCT Code2016-002311-18
NCT CodeNCT03306394


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility